Exploring the Potential Role of Phytopharmaceuticals in Alleviating Toxicities of Chemotherapeutic Agents


如何引用文章

全文:

详细

Background:Chemotherapy is the mainstay of cancer treatment, bringing patients optimism about recurrence and survival. However, the clinical effectiveness of chemotherapeutic drugs is frequently jeopardized by their intrinsic toxicity, resulting in side effects affecting the quality of life of cancer patients. This analysis explores the ethnopharmacological impact of phytopharmaceuticals, highlighting their traditional use in many cultures. The present study, which takes its cues from indigenous knowledge, aims to close the knowledge gap between traditional medicine and modern medicine in reducing the toxicities of chemotherapy treatments.

Aim:The present in-depth study aims to highlight the current research and upcoming developments in phytopharmaceuticals for reducing the toxicity of chemotherapeutic drugs. Further, we address the mechanisms through which phytopharmaceuticals may reduce chemotherapy-induced side effects that include nausea, vomiting, myelosuppression, nephropathy, neuropathy, and cardiotoxicity using data from a variety of preclinical and clinical investigations.

Materials and Methods:The literature search was carried out by employing search engines such as PubMed and Google Scholar with keywords such as cancer, chemotherapy, CNS toxicity, hematopoietic toxicity, renal toxicity, GI toxicity, CNS toxicity, and phytopharmaceuticals.

Results:Bioactive chemicals found in plants, such as fruits, vegetables, herbs, and spices, are being studied for their capacity to improve the safety and acceptability of chemotherapy regimens. The current review also dives into the investigation of phytopharmaceuticals as adjuvant medicines in cancer treatment, which is a viable path for addressing the pressing need to lessen chemotherapy-induced toxicities.

Conclusion:The present review revealed that the potential of phytopharmaceuticals in alleviating chemotherapeutic drug toxicities would pave the way for better cancer treatment and patient outcomes, harmonizing with the larger trend towards personalized and holistic approaches to chemotherapy.

作者简介

Ujwal Katolkar

Department of Pharmacology,, R.C. Patel Institute of Pharmaceutical Education and Research

编辑信件的主要联系方式.
Email: info@benthamscience.net

Sanjay Surana

Department of Pharmacology, R.C. Patel Institute of Pharmaceutical Education and Research

Email: info@benthamscience.net

参考

  1. Mathur, G.; Nain, S.; Sharma, P.K. Cancer: An overview. Acad. J. Cancer Res., 2015, 8(1), 01-9.
  2. Brennan, K; Offiah, G; McSherry, EA; Hopkins, AM Tight junctions: A barrier to the initiation and progression of breast cancer? J. Biomed. Biotechnol., 2010, 2010, 460607.
  3. Zhang, B.; Pan, X.; Cobb, G.P.; Anderson, T.A. microRNAs as oncogenes and tumor suppressors. Dev. Biol., 2007, 302(1), 1-12. doi: 10.1016/j.ydbio.2006.08.028 PMID: 16989803
  4. Hanahan, D.; Weinberg, R.A. The hallmarks of cancer. Cell., 2000, 100(1), 57-70.
  5. Kreeger, P.K.; Lauffenburger, D.A. Cancer systems biology: A network modeling perspective. Carcinogenesis, 2010, 31(1), 2-8. doi: 10.1093/carcin/bgp261 PMID: 19861649
  6. Fu, B.; Wang, N.; Tan, H.Y.; Li, S.; Cheung, F.; Feng, Y. Multi-component herbal products in the prevention and treatment of chemotherapy-associated toxicity and side effects: A review on experimental and clinical evidences. Front. Pharmacol., 2018, 9, 1394. doi: 10.3389/fphar.2018.01394 PMID: 30555327
  7. Koehn, F.E.; Carter, G.T. The evolving role of natural products in drug discovery. Nat. Rev. Drug Discov., 2005, 4(3), 206-220. doi: 10.1038/nrd1657 PMID: 15729362
  8. Ko, J.K.; Auyeung, K.K. Target-oriented mechanisms of novel herbal therapeutics in the chemotherapy of gastrointestinal cancer and inflammation. Curr. Pharm. Des., 2013, 19(1), 48-66. PMID: 22950499
  9. Abbas, Z.; Rehman, S. An overview of cancer treatment modalities. Neoplasm., 2018, 1, 139-157.
  10. Sharma, V; Gupta, A; Sharma, A; Bisht, S; Scholar, UG Extraction of brain tumour using graphical user interface in MATLAB. IJCRT, 2020, 8(6), 1-8.
  11. Menon, S; Thomas, B Use of multi omics data in precision medicine and cancer research with applications in tumor subtyping, prognosis, and diagnosis. Int. J. Adv. Nurs. Edu. Res., 2021, 6(5), 19-29.
  12. Ghoshal, S.; Rigney, G.; Cheng, D.; Brumit, R.; Gee, M.S.; Hodin, R.A.; Lillemoe, K.D.; Levine, W.C.; Succi, M.D. Institutional surgical response and associated volume trends throughout the COVID-19 pandemic and postvaccination recovery period. JAMA Netw. Open, 2022, 5(8), e2227443-e2227443. doi: 10.1001/jamanetworkopen.2022.27443 PMID: 35980636
  13. Yabroff, K.R.; Wu, X.C.; Negoita, S.; Stevens, J.; Coyle, L.; Zhao, J.; Mumphrey, B.J.; Jemal, A.; Ward, K.C. Association of the COVID-19 pandemic with patterns of statewide cancer services. J. Natl. Cancer Inst., 2022, 114(6), 907-909. doi: 10.1093/jnci/djab122 PMID: 34181001
  14. Chen, R.; Aschmann, H.E.; Chen, Y.H.; Glymour, M.M.; Bibbins-Domingo, K.; Stokes, A.C.; Kiang, M.V. Racial and ethnic disparities in estimated excess mortality from external causes in the US, March to December 2020. JAMA Intern. Med., 2022, 182(7), 776-778. doi: 10.1001/jamainternmed.2022.1461 PMID: 35532918
  15. Woolf, S.H.; Chapman, D.A.; Sabo, R.T.; Zimmerman, E.B. Excess deaths from COVID-19 and other causes in the US, March 1, 2020, to January 2, 2021. JAMA, 2021, 325(17), 1786-1789. doi: 10.1001/jama.2021.5199 PMID: 33797550
  16. Gaidai, O.; Yan, P.; Xing, Y. Future world cancer death rate prediction. Sci. Rep., 2023, 13(1), 303. doi: 10.1038/s41598-023-27547-x PMID: 36609490
  17. Ostrom, Q.; Kruchko, C.; Neff, C.; Firth, A.; Sherman, R. The central brain tumor registry of the united states histopathological grouping scheme provides clinically relevant brain and other central nervous system categories for cancer registry data. J. Registry Manag., 2022, 49(4), 139-152. PMID: 37260822
  18. NAACCR. Cancer in North America: 2015-2019. Volume Two: Registry-Specific Cancer Incidence in the United States and Canada North American Association of Central Cancer Registries. Inc. 2022. Available From: https://www.naaccr.org/wp-content/uploads/2022/06/CiNA.2015-2019.v2.incidence.pdf
  19. Liu, B.; Zhu, L.; Zou, J.; Chen, H.S.; Miller, K.D.; Jemal, A.; Siegel, R.L.; Feuer, E.J. Updated methodology for projecting US-and state-level cancer counts for the current calendar year: Part I: Spatio-temporal modeling for cancer incidence. Cancer Epidemiol. Biomarkers Prev., 2021, 30(9), 1620-1626. doi: 10.1158/1055-9965.EPI-20-1727 PMID: 34162657
  20. Miller, K.D.; Siegel, R.L.; Liu, B.; Zhu, L.; Zou, J.; Jemal, A.; Feuer, E.J.; Chen, H.S. Updated methodology for projecting US-and state-level cancer counts for the current calendar year: Part II: Evaluation of incidence and mortality projection methods. Cancer Epidemiol. Biomarkers Prev., 2021, 30(11), 1993-2000. doi: 10.1158/1055-9965.EPI-20-1780 PMID: 34404684
  21. Pickle, L.W.; Hao, Y.; Jemal, A.; Zou, Z.; Tiwari, R.C.; Ward, E.; Hachey, M.; Howe, H.L.; Feuer, E.J. A new method of estimating United States and state-level cancer incidence counts for the current calendar year. CA Cancer J. Clin., 2007, 57(1), 30-42. doi: 10.3322/canjclin.57.1.30 PMID: 17237034
  22. Garraway, L.A.; Lander, E.S. Lessons from the cancer genome. Cell, 2013, 153(1), 17-37. doi: 10.1016/j.cell.2013.03.002 PMID: 23540688
  23. Alexandrov, L.B.; Nik-Zainal, S.; Wedge, D.C.; Aparicio, S.A.J.R.; Behjati, S.; Biankin, A.V.; Bignell, G.R.; Bolli, N.; Borg, A.; Børresen-Dale, A.L.; Boyault, S.; Burkhardt, B.; Butler, A.P.; Caldas, C.; Davies, H.R.; Desmedt, C.; Eils, R.; Eyfjörd, J.E.; Foekens, J.A.; Greaves, M.; Hosoda, F.; Hutter, B.; Ilicic, T.; Imbeaud, S.; Imielinski, M.; Jäger, N.; Jones, D.T.W.; Jones, D.; Knappskog, S.; Kool, M.; Lakhani, S.R.; López-Otín, C.; Martin, S.; Munshi, N.C.; Nakamura, H.; Northcott, P.A.; Pajic, M.; Papaemmanuil, E.; Paradiso, A.; Pearson, J.V.; Puente, X.S.; Raine, K.; Ramakrishna, M.; Richardson, A.L.; Richter, J.; Rosenstiel, P.; Schlesner, M.; Schumacher, T.N.; Span, P.N.; Teague, J.W.; Totoki, Y.; Tutt, A.N.J.; Valdés-Mas, R.; van Buuren, M.M.; van ’t Veer, L.; Vincent-Salomon, A.; Waddell, N.; Yates, L.R.; Zucman-Rossi, J.; Andrew Futreal, P.; McDermott, U.; Lichter, P.; Meyerson, M.; Grimmond, S.M.; Siebert, R.; Campo, E.; Shibata, T.; Pfister, S.M.; Campbell, P.J.; Stratton, M.R. Signatures of mutational processes in human cancer. Nature, 2013, 500(7463), 415-421. doi: 10.1038/nature12477 PMID: 23945592
  24. Negrini, S.; Gorgoulis, V.G.; Halazonetis, T.D. Genomic instability — an evolving hallmark of cancer. Nat. Rev. Mol. Cell Biol., 2010, 11(3), 220-228. doi: 10.1038/nrm2858 PMID: 20177397
  25. Vogelstein, B; Papadopoulos, N; Velculescu, VE; Zhou, S; Diaz, LA, Jr; Kinzler, KW Cancer genome landscapes. Science, 2013, 339(6127), 1546-58. doi: 10.1126/science.1235122
  26. Timp, W.; Feinberg, A.P. Cancer as a dysregulated epigenome allowing cellular growth advantage at the expense of the host. Nat. Rev. Cancer, 2013, 13(7), 497-510. doi: 10.1038/nrc3486 PMID: 23760024
  27. You, J.S.; Jones, P.A. Cancer genetics and epigenetics: Two sides of the same coin? Cancer Cell, 2012, 22(1), 9-20. doi: 10.1016/j.ccr.2012.06.008 PMID: 22789535
  28. Xie, X.; Lu, J.; Kulbokas, E.J.; Golub, T.R.; Mootha, V.; Lindblad-Toh, K.; Lander, E.S.; Kellis, M. Systematic discovery of regulatory motifs in human promoters and 3′ UTRs by comparison of several mammals. Nature, 2005, 434(7031), 338-345. doi: 10.1038/nature03441 PMID: 15735639
  29. Calin, G.A.; Liu, C.G.; Sevignani, C.; Ferracin, M.; Felli, N.; Dumitru, C.D.; Shimizu, M.; Cimmino, A.; Zupo, S.; Dono, M.; Dell’Aquila, M.L.; Alder, H.; Rassenti, L.; Kipps, T.J.; Bullrich, F.; Negrini, M.; Croce, C.M. MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc. Natl. Acad. Sci. USA, 2004, 101(32), 11755-11760. doi: 10.1073/pnas.0404432101 PMID: 15284443
  30. Croce, C.M.; Croce, M.D. Oncogenes and Cancer. N. Engl. J. Med., 2008, 358(5), 502-511. doi: 10.1056/NEJMra072367 PMID: 18234754
  31. Murakami, Y.; Tateyama, S.; Rungsipipat, A.; Uchida, K.; Yamaguchi, R. Amplification of the cyclin A gene in canine and feline mammary tumors. J. Vet. Med. Sci., 2000, 62(7), 783-787. doi: 10.1292/jvms.62.783 PMID: 10945302
  32. Murakami, Y.; Tateyama, S.; Rungsipipat, A.; Uchida, K.; Yamaguchi, R. Immunohistochemical analysis of cyclin A, cyclin D1 and P53 in mammary tumors, squamous cell carcinomas and basal cell tumors of dogs and cats. J. Vet. Med. Sci., 2000, 62(7), 743-750. doi: 10.1292/jvms.62.743 PMID: 10945293
  33. Sherbenou, D.W.; Druker, B.J. Applying the discovery of the Philadelphia chromosome. J. Clin. Invest., 2007, 117(8), 2067-2074. doi: 10.1172/JCI31988 PMID: 17671641
  34. Figueiredo, J.F.; Culver, S.; Behling-Kelly, E.; Breen, M.; Friedrichs, K.R. Acute myeloblastic leukemia with associated BCR-ABL translocation in a dog. Vet. Clin. Pathol., 2012, 41(3), 362-368. doi: 10.1111/j.1939-165X.2012.00450.x PMID: 22747755
  35. Breen, M.; Modiano, J.F. Evolutionarily conserved cytogenetic changes in hematological malignancies of dogs and humans – man and his best friend share more than companionship. Chromosome Res., 2008, 16(1), 145-154. doi: 10.1007/s10577-007-1212-4 PMID: 18293109
  36. Cruz Cardona, J.A.; Milner, R.; Alleman, A.R.; Williams, C.; Vernau, W.; Breen, M.; Tompkins, M. BCR-ABL translocation in a dog with chronic monocytic leukemia. Vet. Clin. Pathol., 2011, 40(1), 40-47. doi: 10.1111/j.1939-165X.2010.00277.x PMID: 21143615
  37. Culver, S.; Ito, D.; Borst, L.; Bell, J.S.; Modiano, J.F.; Breen, M. Molecular characterization of canine BCR-ABL–positive chronic myelomonocytic leukemia before and after chemotherapy. Vet. Clin. Pathol., 2013, 42(3), 314-322. doi: 10.1111/vcp.12055 PMID: 23800034
  38. Misdorp, W.; Meuten, D.J. Tumors in domestic animals; , 2002.
  39. Moulton, J.E. Tumors in domestic animals; Univ of California Press, 1978.
  40. Pietras, K.; Östman, A. Hallmarks of cancer: Interactions with the tumor stroma. Exp. Cell Res., 2010, 316(8), 1324-1331. doi: 10.1016/j.yexcr.2010.02.045 PMID: 20211171
  41. Boyle, J.O.; Hakim, J.; Koch, W.; van der Riet, P.; Hruban, R.H.; Roa, R.A.; Correo, R.; Eby, Y.J.; Ruppert, J.M.; Sidransky, D. The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Res., 1993, 53(19), 4477-4480. PMID: 8402617
  42. Bieging, K.T.; Mello, S.S.; Attardi, L.D. Unravelling mechanisms of p53-mediated tumour suppression. Nat. Rev. Cancer, 2014, 14(5), 359-370. doi: 10.1038/nrc3711 PMID: 24739573
  43. Burkhart, D.L.; Sage, J. Cellular mechanisms of tumour suppression by the retinoblastoma gene. Nat. Rev. Cancer, 2008, 8(9), 671-682. doi: 10.1038/nrc2399 PMID: 18650841
  44. Olivier, M; Hollstein, M; Hainaut, P. TP53 mutations in human cancers: Origins, consequences, and clinical use. Cold Spring Harb Perspect Biol., 2010, 2(1), a001008.
  45. Diller, L.; Kassel, J.; Nelson, C.E.; Gryka, M.A.; Litwak, G.; Gebhardt, M.; Bressac, B.; Ozturk, M.; Baker, S.J.; Vogelstein, B. p53 functions as a cell cycle control protein in osteosarcomas. Mol. Cell. Biol., 1990, 10(11), 5772-5781. PMID: 2233717
  46. Cullen, J.M.; Breen, M. An overview of molecular cancer pathogenesis, prognosis, and diagnosis; Tumors Domest Anim, 2016, pp. 1-26. doi: 10.1002/9781119181200.ch1
  47. Tian, H.; Faje, A.T.; Lee, S.L.; Jorgensen, T.J. Radiation-induced phosphorylation of Chk1 at S345 is associated with p53-dependent cell cycle arrest pathways. Neoplasia, 2002, 4(2), 171-180. doi: 10.1038/sj.neo.7900219 PMID: 11896572
  48. Bernstein, C.; Bernstein, H.; Payne, C.M.; Garewal, H. DNA repair/pro-apoptotic dual-role proteins in five major DNA repair pathways: Fail-safe protection against carcinogenesis. Mutat. Res. Rev. Mutat. Res., 2002, 511(2), 145-178. doi: 10.1016/S1383-5742(02)00009-1 PMID: 12052432
  49. Rayess, H.; Wang, M.B.; Srivatsan, E.S. Cellular senescence and tumor suppressor gene p16. Int. J. Cancer, 2012, 130(8), 1715-1725. doi: 10.1002/ijc.27316 PMID: 22025288
  50. Alhmoud, J.F.; Woolley, J.F.; Al Moustafa, A.E.; Mallei, M.I. DNA damage/repair management in cancers. In: Adv. Med. Biochem. Genomics, Physiol. Pathol; , 2021; pp. 309-339.
  51. Wright, W.E.; Shay, J.W. Telomere dynamics in cancer progression and prevention: Fundamental differences in human and mouse telomere biology. Nat. Med., 2000, 6(8), 849-851. doi: 10.1038/78592 PMID: 10932210
  52. Novak, K.D. Telomeres and telomerases in cancer. MedGenMed, 2003, 5(1), 21. PMID: 12827082
  53. Renwick, M.G.; Argyle, D.J.; Long, S.; Nixon, C.; Gault, E.A.; Nasir, L. Telomerase activity and telomerase reverse transcriptase catalytic subunit expression in canine lymphoma: Correlation with Ki67 immunoreactivity. Vet. Comp. Oncol., 2006, 4(3), 141-150. doi: 10.1111/j.1476-5829.2006.00103.x PMID: 19754811
  54. Hanahan, D.; Folkman, J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell, 1996, 86(3), 353-364. doi: 10.1016/S0092-8674(00)80108-7 PMID: 8756718
  55. Debela, D.T.; Muzazu, S.G.Y.; Heraro, K.D.; Ndalama, M.T.; Mesele, B.W.; Haile, D.C.; Kitui, S.K.; Manyazewal, T. New approaches and procedures for cancer treatment: Current perspectives. SAGE Open Med., 2021, 9, 20503121211034366. doi: 10.1177/20503121211034366 PMID: 34408877
  56. Goss, P.E.; Strasser-Weippl, K.; Lee-Bychkovsky, B.L.; Fan, L.; Li, J.; Chavarri-Guerra, Y.; Liedke, P.E.R.; Pramesh, C.S.; Badovinac-Crnjevic, T.; Sheikine, Y.; Chen, Z.; Qiao, Y.; Shao, Z.; Wu, Y.L.; Fan, D.; Chow, L.W.C.; Wang, J.; Zhang, Q.; Yu, S.; Shen, G.; He, J.; Purushotham, A.; Sullivan, R.; Badwe, R.; Banavali, S.D.; Nair, R.; Kumar, L.; Parikh, P.; Subramanian, S.; Chaturvedi, P.; Iyer, S.; Shastri, S.S.; Digumarti, R.; Soto-Perez-de-Celis, E.; Adilbay, D.; Semiglazov, V.; Orlov, S.; Kaidarova, D.; Tsimafeyeu, I.; Tatishchev, S.; Danishevskiy, K.D.; Hurlbert, M.; Vail, C.; St Louis, J.; Chan, A. Challenges to effective cancer control in China, India, and Russia. Lancet Oncol., 2014, 15(5), 489-538. doi: 10.1016/S1470-2045(14)70029-4 PMID: 24731404
  57. Purushotham, A.D.; Lewison, G.; Sullivan, R. The state of research and development in global cancer surgery. Ann. Surg., 2012, 255(3), 427-432. doi: 10.1097/SLA.0b013e318246591f PMID: 22281701
  58. Vasen, H.; Watson, P.; Mecklin, J.; Lynch, H. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative Group on HNPCC. Gastroenterology, 1999, 116(6), 1453-1456. doi: 10.1016/S0016-5085(99)70510-X PMID: 10348829
  59. Ringborg, U.; Bergqvist, D.; Brorsson, B.; Cavallin-ståhl, E.; Ceberg, J.; Einhorn, N.; Frödin, J.; Järhult, J.; Lamnevik, G.; Lindholm, C.; Littbrand, B.; Norlund, A.; Nylén, U.; Rosén, M.; Svensson, H.; Möller, T.R. The Swedish Council on Technology Assessment in Health Care (SBU) systematic overview of radiotherapy for cancer including a prospective survey of radiotherapy practice in Sweden 2001--summary and conclusions. Acta Oncol., 2003, 42(5-6), 357-365. doi: 10.1080/02841860310010826 PMID: 14596499
  60. Delaney, G.; Jacob, S.; Featherstone, C.; Barton, M. The role of radiotherapy in cancer treatment. Cancer, 2005, 104(6), 1129-1137. doi: 10.1002/cncr.21324 PMID: 16080176
  61. Begg, A.C.; Stewart, F.A.; Vens, C. Strategies to improve radiotherapy with targeted drugs. Nat. Rev. Cancer, 2011, 11(4), 239-253. doi: 10.1038/nrc3007 PMID: 21430696
  62. Barnett, G.C.; West, C.M.L.; Dunning, A.M.; Elliott, R.M.; Coles, C.E.; Pharoah, P.D.P.; Burnet, N.G. Normal tissue reactions to radiotherapy: Towards tailoring treatment dose by genotype. Nat. Rev. Cancer, 2009, 9(2), 134-142. doi: 10.1038/nrc2587 PMID: 19148183
  63. Bernier, J.; Hall, E.J.; Giaccia, A. Radiation oncology: A century of achievements. Nat. Rev. Cancer, 2004, 4(9), 737-747. doi: 10.1038/nrc1451 PMID: 15343280
  64. Nygren, P. What is cancer chemotherapy? Acta Oncol., 2001, 40(2-3), 166-174. doi: 10.1080/02841860151116204 PMID: 11441929
  65. Pratt, W.B. The anticancer drugs; Oxford University Press: USA, 1994.
  66. Johnson, S.W. Cisplatin and its analogues; Cancer Princ Pract Oncol, 2005.
  67. Verweij, J.; Clavel, M.; Chevalier, B. Paclitaxel (TaxolTM) and docetaxel (TaxotereTM): Not simply two of a kind. Ann. Oncol., 1994, 5(6), 495-505. doi: 10.1093/oxfordjournals.annonc.a058903 PMID: 7918121
  68. Dancey, J.; Eisenhauer, E.A. Current perspectives on camptothecins in cancer treatment. Br. J. Cancer, 1996, 74(3), 327-338. doi: 10.1038/bjc.1996.362 PMID: 8695345
  69. Gyanani, V. Turning stealth liposomes into cationic liposomes for anticancer drug delivery., 2013,
  70. Allen, T.M. Ligand-targeted therapeutics in anticancer therapy. Nat. Rev. Cancer, 2002, 2(10), 750-763. doi: 10.1038/nrc903 PMID: 12360278
  71. Yao, X.; Panichpisal, K.; Kurtzman, N.; Nugent, K. Cisplatin nephrotoxicity: A review. Am. J. Med. Sci., 2007, 334(2), 115-124. doi: 10.1097/MAJ.0b013e31812dfe1e PMID: 17700201
  72. Pfeffer, B.; Tziros, C.; Katz, R.J. Current concepts of anthracycline cardiotoxicity: Pathogenesis, diagnosis and prevention. Br. J. Cardiol., 2009, 16(2)
  73. Partridge, A.H.; Burstein, H.J.; Winer, E.P. Side effects of chemotherapy and combined chemohormonal therapy in women with early-stage breast cancer. J. Natl. Cancer Inst. Monogr., 2001, 2001(30), 135-142. doi: 10.1093/oxfordjournals.jncimonographs.a003451 PMID: 11773307
  74. Fabbrocini, G.; Cameli, N.; Romano, M.C.; Mariano, M.; Panariello, L.; Bianca, D.; Monfrecola, G. Chemotherapy and skin reactions. J. Exp. Clin. Cancer Res., 2012, 31(1), 50. doi: 10.1186/1756-9966-31-50 PMID: 22640460
  75. de Vries Schultink, A.H.M.; Suleiman, A.A.; Schellens, J.H.M.; Beijnen, J.H.; Huitema, A.D.R. Pharmacodynamic modeling of adverse effects of anti-cancer drug treatment. Eur. J. Clin. Pharmacol., 2016, 72(6), 645-653. doi: 10.1007/s00228-016-2030-4 PMID: 26915815
  76. Vadhan-Raj, S. Management of chemotherapy-induced thrombocytopenia: Current status of thrombopoietic agents. Seminars in Hematology; Elsevier, 2009, pp. S26-S32. doi: 10.1053/j.seminhematol.2008.12.007
  77. Crawford, J.; Dale, D.C.; Lyman, G.H. Chemotherapy-induced neutropenia. Cancer, 2004, 100(2), 228-237. doi: 10.1002/cncr.11882 PMID: 14716755
  78. Lyman, G.H.; Poniewierski, M.S.; Culakova, E. Risk of chemotherapy-induced neutropenic complications when treating patients with non-Hodgkin lymphoma. Expert Opin. Drug Saf., 2016, 15(4), 483-492. doi: 10.1517/14740338.2016.1146675 PMID: 26809103
  79. Feng, L.; Huang, Q.; Huang, Z.; Li, H.; Qi, X.; Wang, Y.; Liu, Z.; Liu, X.; Lu, L. Optimized animal model of cyclophosphamide-induced bone marrow suppression. Basic Clin. Pharmacol. Toxicol., 2016, 119(5), 428-435. doi: 10.1111/bcpt.12600 PMID: 27061017
  80. Ma, R.M.; Chen, C.Z.; Zhang, W.; You, J.; Huang, D.P.; Guo, G.L. Prognostic value of chemotherapy-induced neutropenia at the first cycle in invasive breast cancer. Medicine (Baltimore), 2016, 95(13), e3240. doi: 10.1097/MD.0000000000003240 PMID: 27043697
  81. Barreto, J.N.; McCullough, K.B.; Ice, L.L.; Smith, J.A. Antineoplastic agents and the associated myelosuppressive effects: A review. J. Pharm. Pract., 2014, 27(5), 440-446. doi: 10.1177/0897190014546108 PMID: 25147158
  82. Kukec, R.R.; Grabnar, I.; Vovk, T.; Mrhar, A.; Kovac, V.; Cufer, T. Febrile neutropenia in chemotherapy treated small-cell lung cancer patients. Radiol. Oncol., 2015, 49(2), 173-180. doi: 10.2478/raon-2014-0050 PMID: 26029029
  83. Andersohn, F.; Konzen, C.; Garbe, E. Systematic review: Agranulocytosis induced by nonchemotherapy drugs. Ann. Intern. Med., 2007, 146(9), 657-665. doi: 10.7326/0003-4819-146-9-200705010-00009 PMID: 17470834
  84. Kaufman, D.W.; Kelly, J.P.; Issaragrisil, S.; Laporte, J.R.; Anderson, T.; Levy, M.; Shapiro, S.; Young, N.S. Relative incidence of agranulocytosis and aplastic anemia. Am. J. Hematol., 2006, 81(1), 65-67. doi: 10.1002/ajh.20489 PMID: 16369972
  85. Printz, M.A.; Dychter, S.S.; DeNoia, E.P.; Harrigan, R.; Sugarman, B.J.; Zepeda, M.; Souratha, J.; Kang, D.W.; Maneval, D.C. A phase I study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of recombinant human hyaluronidase PH20 administered intravenously in healthy volunteers. Curr. Ther. Res. Clin. Exp., 2020, 93, 100604. doi: 10.1016/j.curtheres.2020.100604 PMID: 32963641
  86. Johnson, P.; Glennie, M. The mechanisms of action of rituximab in the elimination of tumor cells.Seminars in oncology; Elsevier, 2003, pp. 3-8. doi: 10.1053/sonc.2003.50025
  87. Motl, S.E.; Baskin, R.C. Delayed-onset grade 4 neutropenia associated with rituximab therapy in a patient with lymphoma: Case report and literature review. Pharmacotherapy, 2005, 25(8), 1151-1155. doi: 10.1592/phco.2005.25.8.1151 PMID: 16207108
  88. Nitta, E.; Izutsu, K.; Sato, T.; Ota, Y.; Takeuchi, K.; Kamijo, A.; Takahashi, K.; Oshima, K.; Kanda, Y.; Chiba, S.; Motokura, T.; Kurokawa, M. A high incidence of late-onset neutropenia following rituximab-containing chemotherapy as a primary treatment of CD20-positive B-cell lymphoma: A single-institution study. Ann. Oncol., 2007, 18(2), 364-369. doi: 10.1093/annonc/mdl393 PMID: 17079695
  89. Hirayama, Y.; Kohda, K.; Konuma, Y.; Hirata, Y.; Kuroda, H.; Fujimi, Y.; Shirao, S.; Kobune, M.; Takimoto, R.; Matsunaga, T.; Kato, J. Late onset neutropenia and immunoglobulin suppression of the patients with malignant lymphoma following autologous stem cell transplantation with rituximab. Intern. Med., 2009, 48(1), 57-60. doi: 10.2169/internalmedicine.48.1368 PMID: 19122357
  90. National Cancer Institute (NCI). Common Terminology Criteria for Adverse Events v3.0 (CTCAE). 2006. Available From: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf
  91. Kuter, D.J. General aspects of thrombocytopenia, platelet transfusions, and thrombopoietic growth factors.Consultative hemostasis and thrombosis; Elsevier, 2019, pp. 108-126. doi: 10.1016/B978-0-323-46202-0.00007-8
  92. Schmied, L.; Höglund, P.; Meinke, S. Platelet-mediated protection of cancer cells from immune surveillance–possible implications for cancer immunotherapy. Front. Immunol., 2021, 12, 640578. doi: 10.3389/fimmu.2021.640578 PMID: 33777033
  93. Wright, J.H. A rapid method for the differential staining of blood films and malarial parasites. J. Med. Res., 1902, 7(1), 138-144. PMID: 19971449
  94. Potts, K.S.; Farley, A.; Dawson, C.A.; Rimes, J.; Biben, C.; de Graaf, C.; Potts, M.A.; Stonehouse, O.J.; Carmagnac, A.; Gangatirkar, P.; Josefsson, E.C.; Anttila, C.; Amann-Zalcenstein, D.; Naik, S.; Alexander, W.S.; Hilton, D.J.; Hawkins, E.D.; Taoudi, S. Membrane budding is a major mechanism of in vivo platelet biogenesis. J. Exp. Med., 2020, 217(9), e20191206. doi: 10.1084/jem.20191206 PMID: 32706855
  95. Balduini, C.L. 100-Year-Old Haematologica Images: The Quarrel About The Origin Of Platelets (II). Haematologica, 2020, 105(6), 1467. doi: 10.3324/haematol.2020.254011 PMID: 32482749
  96. Skverchinskaya, E.; Levdarovich, N.; Ivanov, A.; Mindukshev, I.; Bukatin, A. Anticancer drugs paclitaxel, carboplatin, doxorubicin, and cyclophosphamide alter the biophysical characteristics of red blood cells, in vitro. Biology (Basel), 2023, 12(2), 230. doi: 10.3390/biology12020230 PMID: 36829507
  97. Jordan, M.A.; Wilson, L. Microtubules as a target for anticancer drugs. Nat. Rev. Cancer, 2004, 4(4), 253-265. doi: 10.1038/nrc1317 PMID: 15057285
  98. Kelland, L. The resurgence of platinum-based cancer chemotherapy. Nat. Rev. Cancer, 2007, 7(8), 573-584. doi: 10.1038/nrc2167 PMID: 17625587
  99. Minotti, G.; Menna, P.; Salvatorelli, E.; Cairo, G.; Gianni, L. Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev., 2004, 56(2), 185-229. doi: 10.1124/pr.56.2.6 PMID: 15169927
  100. Colombo, R.; Necco, A.; Vailati, G.; Milzani, A. Dose-dependence of doxorubicin effect on actin assembly in vitro. Exp. Mol. Pathol., 1988, 49(3), 297-304. doi: 10.1016/0014-4800(88)90002-0 PMID: 3197812
  101. Alves, A.C.; Ribeiro, D.; Nunes, C.; Reis, S. Biophysics in cancer: The relevance of drug-membrane interaction studies. Biochim. Biophys. Acta Biomembr., 2016, 1858(9), 2231-2244. doi: 10.1016/j.bbamem.2016.06.025 PMID: 27368477
  102. Shinohara, K.; Tanaka, K.R. The effects of adriamycin (doxorubicin HCl) on human red blood cells. Hemoglobin, 1980, 4(5-6), 735-745. doi: 10.3109/03630268008997741 PMID: 6254923
  103. Lyman, G.H.; Dale, D.C.; Crawford, J. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: A nationwide study of community practices. J. Clin. Oncol., 2003, 21(24), 4524-4531. doi: 10.1200/JCO.2003.05.002 PMID: 14673039
  104. Lyman, G.H.; Dale, D.C.; Friedberg, J.; Crawford, J.; Fisher, R.I. Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin’s lymphoma: A nationwide study. J. Clin. Oncol., 2004, 22(21), 4302-4311. doi: 10.1200/JCO.2004.03.213 PMID: 15381684
  105. Mauch, P.; Constine, L.; Greenberger, J.; Knospe, W.; Sullivan, J.; Liesveld, J.L.; Deeg, H.J. Hematopoietic stem cell compartment: Acute and late effects of radiation therapy and chemotherapy. Int. J. Radiat. Oncol. Biol. Phys., 1995, 31(5), 1319-1339. doi: 10.1016/0360-3016(94)00430-S PMID: 7713791
  106. Marsh, J.C. The effects of cancer chemotherapeutic agents on normal hematopoietic precursor cells: A review. Cancer Res., 1976, 36(6), 1853-1882. PMID: 773531
  107. Bonfield, T.L.; Farver, C.F.; Barna, B.P.; Malur, A.; Abraham, S.; Raychaudhuri, B.; Kavuru, M.S.; Thomassen, M.J. Peroxisome proliferator-activated receptor-γ is deficient in alveolar macrophages from patients with alveolar proteinosis. Am. J. Respir. Cell Mol. Biol., 2003, 29(6), 677-682. doi: 10.1165/rcmb.2003-0148OC PMID: 12805087
  108. Schmiegelow, K.; Attarbaschi, A.; Barzilai, S.; Escherich, G.; Frandsen, T.L.; Halsey, C.; Hough, R.; Jeha, S.; Kato, M.; Liang, D.C.; Mikkelsen, T.S.; Möricke, A.; Niinimäki, R.; Piette, C.; Putti, M.C.; Raetz, E.; Silverman, L.B.; Skinner, R.; Tuckuviene, R.; van der Sluis, I.; Zapotocka, E. Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: A Delphi consensus. Lancet Oncol., 2016, 17(6), e231-e239. doi: 10.1016/S1470-2045(16)30035-3 PMID: 27299279
  109. Braña, I.; Zamora, E.; Tabernero, J. Cardiotoxicity; Side Eff Med Cancer Ther Prev Treat, 2013, pp. 483-530.
  110. Cardinale, D.; Colombo, A.; Lamantia, G.; Colombo, N.; Civelli, M.; De Giacomi, G.; Rubino, M.; Veglia, F.; Fiorentini, C.; Cipolla, C.M. Anthracycline-Induced Cardiomyopathy. J. Am. Coll. Cardiol., 2010, 55(3), 213-220. doi: 10.1016/j.jacc.2009.03.095 PMID: 20117401
  111. Steinherz, L.J.; Steinherz, P.G.; Tan, C.T.C.; Heller, G.; Murphy, M.L. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA, 1991, 266(12), 1672-1677. doi: 10.1001/jama.1991.03470120074036 PMID: 1886191
  112. Florescu, M.; Cinteza, M.; Vinereanu, D. Chemotherapy-induced Cardiotoxicity. Maedica (Buchar.), 2013, 8(1), 59-67. PMID: 24023601
  113. Khakoo, A.Y.; Liu, P.P.; Force, T.; Lopez-Berestein, G.; Jones, L.W.; Schneider, J.; Hill, J. Cardiotoxicity due to cancer therapy. Tex. Heart Inst. J., 2011, 38(3), 253-256. PMID: 21720463
  114. Jensen, B.V. Cardiotoxic consequences of anthracycline-containing therapy in patients with breast cancer. Seminars in oncology; Elsevier, 2006, pp. 15-21. doi: 10.1053/j.seminoncol.2006.04.022
  115. Jiji, R.S.; Kramer, C.M.; Salerno, M. Non-invasive imaging and monitoring cardiotoxicity of cancer therapeutic drugs. J. Nucl. Cardiol., 2012, 19(2), 377-388. doi: 10.1007/s12350-012-9512-2 PMID: 22351492
  116. Seidman, A.; Hudis, C.; Pierri, M.K.; Shak, S.; Paton, V.; Ashby, M.; Murphy, M.; Stewart, S.J.; Keefe, D. Cardiac dysfunction in the trastuzumab clinical trials experience. J. Clin. Oncol., 2002, 20(5), 1215-1221. doi: 10.1200/JCO.2002.20.5.1215 PMID: 11870163
  117. Dolci, A.; Dominici, R.; Cardinale, D.; Sandri, M.T.; Panteghini, M. Biochemical markers for prediction of chemotherapy-induced cardiotoxicity: Systematic review of the literature and recommendations for use. Am. J. Clin. Pathol., 2008, 130(5), 688-695. doi: 10.1309/AJCPB66LRIIVMQDR PMID: 18854260
  118. DeAngelis, L.M. Side effects of radiation therapy.Neurologic Complications of Cancer; DeAngelis, L.M.; Posner, J.B., Eds.; Oxford University Press: New York, 2009.
  119. Orlopp, K.; Schmidt-Wolf, I.G.H.; Urbach, H.; Schlegel, U. Acute central nervous symptoms in oncologic patients. Internist (Berl.), 2005, 46(1), 19-29. doi: 10.1007/s00108-004-1315-3 PMID: 15580462
  120. Ziske, C.G.; Schöttker, B.; Gorschlüter, M.; Mey, U.; Kleinschmidt, R.; Schlegel, U.; Sauerbruch, T.; Schmidt-Wolf, I.G.H. Acute transient encephalopathy after paclitaxel infusion: Report of three cases. Ann. Oncol., 2002, 13(4), 629-631. doi: 10.1093/annonc/mdf025 PMID: 12056715
  121. Verstappen, C.C.P.; Heimans, J.J.; Hoekman, K.; Postma, T.J. Neurotoxic complications of chemotherapy in patients with cancer: Clinical signs and optimal management. Drugs, 2003, 63(15), 1549-1563. doi: 10.2165/00003495-200363150-00003 PMID: 12887262
  122. Linnebank, M.; Pels, H.; Kleczar, N.; Farmand, S.; Fliessbach, K.; Urbach, H.; Orlopp, K.; Klockgether, T.; Schmidt-Wolf, I.G.H.; Schlegel, U. MTX-induced white matter changes are associated with polymorphisms of methionine metabolism. Neurology, 2005, 64(5), 912-913. doi: 10.1212/01.WNL.0000152840.26156.74 PMID: 15753437
  123. Linnebank, M.; Moskau, S.; Jürgens, A.; Simon, M.; Semmler, A.; Orlopp, K.; Glasmacher, A.; Bangard, C.; Vogt-Schaden, M.; Urbach, H.; Schmidt-Wolf, I.G.H.; Pels, H.; Schlegel, U. Association of genetic variants of methionine metabolism with methotrexate-induced CNS white matter changes in patients with primary CNS lymphoma. Neuro-oncol., 2009, 11(1), 2-8. doi: 10.1215/15228517-2008-082 PMID: 18806228
  124. Drachtman, R.A.; Cole, P.D.; Golden, C.B.; James, S.J.; Melnyk, S.; Aisner, J.; Kamen, B.A. Dextromethorphan is effective in the treatment of subacute methotrexate neurotoxicity. Pediatr. Hematol. Oncol., 2002, 19(5), 319-327. doi: 10.1080/08880010290057336 PMID: 12078863
  125. Becker, A.; Vezmar, S.; Linnebank, M.; Pels, H.; Bode, U.; Schlegel, U.; Jaehde, U. Marked elevation in homocysteine and homocysteine sulfinic acid in the cerebrospinal fluid of lymphoma patients receiving intensive treatment with methotrexate. Int. J. Clin. Pharmacol. Ther., 2007, 45(9), 504-515. doi: 10.5414/CPP45504 PMID: 17907593
  126. Perazella, M.A. Onco-Nephrology. Clin. J. Am. Soc. Nephrol., 2012, 7(10), 1713-1721. doi: 10.2215/CJN.02780312 PMID: 22879440
  127. Santos, M.L.C.; Brito, B.B.; Silva, F.A.F.; Botelho, A.C.S.; Melo, F.F. Nephrotoxicity in cancer treatment: An overview. World J. Clin. Oncol., 2020, 11(4), 190-204. doi: 10.5306/wjco.v11.i4.190 PMID: 32355641
  128. Małyszko, J.; Kozłowska, K.; Kozłowski, L.; Małyszko, J. Nephrotoxicity of anticancer treatment. Nephrol. Dial. Transplant., 2017, 32(6), 924-936. PMID: 28339935
  129. Perazella, M.A.; Shirali, A.C. Nephrotoxicity of cancer immunotherapies: Past, present and future. J. Am. Soc. Nephrol., 2018, 29(8), 2039-2052. doi: 10.1681/ASN.2018050488 PMID: 29959196
  130. Totzeck, M.; Schuler, M.; Stuschke, M.; Heusch, G.; Rassaf, T. Cardio-oncology - strategies for management of cancer-therapy related cardiovascular disease. Int. J. Cardiol., 2019, 280, 163-175. doi: 10.1016/j.ijcard.2019.01.038 PMID: 30661849
  131. Stone, J.B.; DeAngelis, L.M. Cancer-treatment-induced neurotoxicity—focus on newer treatments. Nat. Rev. Clin. Oncol., 2016, 13(2), 92-105. doi: 10.1038/nrclinonc.2015.152 PMID: 26391778
  132. Perazella, M.A.; Izzedine, H. New drug toxicities in the onco-nephrology world. Kidney Int., 2015, 87(5), 909-917. doi: 10.1038/ki.2015.30 PMID: 25671763
  133. Choti, M.A. Chemotherapy-associated hepatotoxicity: Do we need to be concerned? Ann. Surg. Oncol., 2009, 16(9), 2391-2394. doi: 10.1245/s10434-009-0512-7 PMID: 19554374
  134. Jaeschke, H.; Gores, G.J.; Cederbaum, A.I.; Hinson, J.A.; Pessayre, D.; Lemasters, J.J. Mechanisms of Hepatotoxicity. Toxicol. Sci., 2002, 65(2), 166-176. doi: 10.1093/toxsci/65.2.166 PMID: 11812920
  135. Fontana, R.J. Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives. Gastroenterology, 2014, 146(4), 914-928.e1. doi: 10.1053/j.gastro.2013.12.032 PMID: 24389305
  136. Hoofnagle, J.H.; Björnsson, E.S. Drug-induced liver injury—types and phenotypes. N. Engl. J. Med., 2019, 381(3), 264-273. doi: 10.1056/NEJMra1816149 PMID: 31314970
  137. Björnsson, E. Hepatotoxicity by drugs: The most common implicated agents. Int. J. Mol. Sci., 2016, 17(2), 224. doi: 10.3390/ijms17020224 PMID: 26861310
  138. Mudd, T.W.; Guddati, A.K. Management of hepatotoxicity of chemotherapy and targeted agents. Am. J. Cancer Res., 2021, 11(7), 3461-3474. PMID: 34354855
  139. Floyd, J.; Mirza, I.; Sachs, B.; Perry, M.C. Hepatotoxicity of Chemotherapy. Semin. Oncol., 2006, 33(1), 50-67. doi: 10.1053/j.seminoncol.2005.11.002 PMID: 16473644
  140. Grigorian, A.; O’Brien, C.B. Hepatotoxicity secondary to chemotherapy. J. Clin. Transl. Hepatol., 2014, 2(2), 95-102. PMID: 26357620
  141. Periáñez-Párraga, L.; Martínez-López, I.; Ventayol-Bosch, P.; Puigventós-Latorre, F.; Delgado-Sánchez, O. Drug dosage recommendations in patients with chronic liver disease. Rev. Esp. Enferm. Dig., 2012, 104(4), 165-184. doi: 10.4321/S1130-01082012000400002 PMID: 22537365
  142. Choi, S.H. WHO traditional medicine strategy and activities. "Standardization with evidence-based approaches". J. Acupunct. Meridian Stud., 2008, 1(2), 153-154. doi: 10.1016/S2005-2901(09)60037-6 PMID: 20633469
  143. Cho, HJ; Yoon, IS Pharmacokinetic interactions of herbs with cytochrome p450 and p-glycoprotein.es". Evid Based Complement. Alternat. Med., 2015, 2015, 736431. doi: 10.1155/2015/736431
  144. Oyebode, O.; Kandala, N.B.; Chilton, P.J.; Lilford, R.J. Use of traditional medicine in middle-income countries: A WHO-SAGE study. Health Policy Plan., 2016, 31(8), 984-991. doi: 10.1093/heapol/czw022 PMID: 27033366
  145. Asiimwe, J.B.; Nagendrappa, P.B.; Atukunda, E.C.; Kamatenesi, M.M.; Nambozi, G.; Tolo, C.U.; Ogwang, P.E.; Sarki, A.M. Prevalence of the use of herbal medicines among patients with cancer: A systematic review and meta-analysis. Evid. Based Complement. Alternat. Med., 2021, 2021, 1-18. doi: 10.1155/2021/9963038 PMID: 34055029
  146. McGrowder, D.A.; Miller, F.G.; Nwokocha, C.R.; Anderson, M.S.; Wilson-Clarke, C.; Vaz, K.; Anderson-Jackson, L.; Brown, J. Medicinal herbs used in traditional management of breast cancer: Mechanisms of action. Medicines (Basel), 2020, 7(8), 47. doi: 10.3390/medicines7080047 PMID: 32823812
  147. Damery, S.; Gratus, C.; Grieve, R.; Warmington, S.; Jones, J.; Routledge, P.; Greenfield, S.; Dowswell, G.; Sherriff, J.; Wilson, S. The use of herbal medicines by people with cancer: A cross-sectional survey. Br. J. Cancer, 2011, 104(6), 927-933. doi: 10.1038/bjc.2011.47 PMID: 21364591
  148. Molassiotis, A.; Yung, H.P.; Yam, B.M.; Chan, F.Y.; Mok, T. The effectiveness of progressive muscle relaxation training in managing chemotherapy-induced nausea and vomiting in Chinese breast cancer patients: A randomised controlled trial. Support. Care Cancer, 2002, 10(3), 237-246. doi: 10.1007/s00520-001-0329-9 PMID: 11904789
  149. Maimon, Y.; Samuels, N.; Cohen, Z.; Berger, R.; Rosenthal, D.S. Botanical formula LCS101: A multi-targeted approach to cancer care. Integr. Cancer Ther., 2018, 17(4), 1020-1026. doi: 10.1177/1534735418801528 PMID: 30303021
  150. Cohen, Z.; Maimon, Y.; Yoeli-Lerner, M.; Yang, P.; Samuels, N.; Berger, R. Selective anticancer effects and protection from chemotherapy by the botanical compound LCS101: Implications for cancer treatment. Int. J. Oncol., 2015, 46(1), 308-316. doi: 10.3892/ijo.2014.2711 PMID: 25333773
  151. Maimon, Y.; Karaush, V.; Yaal-Hahoshen, N.; Ben-Yosef, R.; Ron, I.; Vexler, A.; Lev-Ari, S. Effect of Chinese herbal therapy on breast cancer adenocarcinoma cell lines. J. Int. Med. Res., 2010, 38(6), 2033-2039. doi: 10.1177/147323001003800617 PMID: 21227007
  152. Yaal-Hahoshen, N.; Maimon, Y.; Siegelmann-Danieli, N.; Lev-Ari, S.; Ron, I.G.; Sperber, F.; Samuels, N.; Shoham, J.; Merimsky, O. A prospective, controlled study of the botanical compound mixture LCS101 for chemotherapy-induced hematological complications in breast cancer. Oncologist, 2011, 16(9), 1197-1202. doi: 10.1634/theoncologist.2011-0150 PMID: 21712486
  153. Kawai, H.; Saito, Y. Combination of Juzentaihoto and chemotherapy improves the prognosis of patients with postoperative recurrence of non‑small cell lung cancer. Mol. Clin. Oncol., 2020, 13(3), 13. doi: 10.3892/mco.2020.2083 PMID: 32754327
  154. Testart-Paillet, D.; Girard, P.; You, B.; Freyer, G.; Pobel, C.; Tranchand, B. Contribution of modelling chemotherapy-induced hematological toxicity for clinical practice. Crit. Rev. Oncol. Hematol., 2007, 63(1), 1-11. doi: 10.1016/j.critrevonc.2007.01.005 PMID: 17418588
  155. Kambhampati, S.P.; Mishra, M.K.; Mastorakos, P.; Oh, Y.; Lutty, G.A.; Kannan, R.M. Intracellular delivery of dendrimer triamcinolone acetonide conjugates into microglial and human retinal pigment epithelial cells. Eur. J. Pharm. Biopharm., 2015, 95(Pt B), 239-249. doi: 10.1016/j.ejpb.2015.02.013 PMID: 25701805
  156. Teschke, R.; Wolff, A.; Frenzel, C.; Eickhoff, A.; Schulze, J. Herbal traditional Chinese medicine and its evidence base in gastrointestinal disorders. World J. Gastroenterol., 2015, 21(15), 4466-4490. doi: 10.3748/wjg.v21.i15.4466 PMID: 25914456
  157. Li, H; Ma, Q; Al, P; Zhang, HM; Li, M Treatment of chemotherapy-induced leucopenia in patients with malignant tumor by Chinese herbal medicine: A systematic review and meta-analysis of randomized clinical trials. Zhongguo Zhong Xi Yi Jie He Za Zhi, 2015, 35(2), 157-66.
  158. Kohguchi, M.; Kunikata, T.; Watanabe, H.; Kudo, N.; Shibuya, T.; Ishihara, T.; Iwaki, K.; Ikeda, M.; Fukuda, S.; Kurimoto, M. Immuno-potentiating effects of the antler-shaped fruiting body of Ganoderma lucidum (Rokkaku-Reishi). Biosci. Biotechnol. Biochem., 2004, 68(4), 881-887. doi: 10.1271/bbb.68.881 PMID: 15118318
  159. Nonaka, Y.; Ishibashi, H.; Nakai, M.; Shibata, H.; Kiso, Y.; Abe, S. Soothing effect of Ganoderma lucidum antlered form on cyclophosphamide-induced adverse reaction. Gan To Kagaku Ryoho, 2005, 32(11), 1586-1588. PMID: 16315878
  160. Zee-Cheng, R.K. Shi-quan-da-bu-tang (ten significant tonic decoction), SQT. A potent Chinese biological response modifier in cancer immunotherapy, potentiation and detoxification of anticancer drugs. Methods Find. Exp. Clin. Pharmacol., 1992, 14(9), 725-736. PMID: 1294861
  161. Vayalil, P.K.; Kuttan, G.; Kuttan, R. Rasayanas: Evidence for the concept of prevention of diseases. Am. J. Chin. Med., 2002, 30(1), 155-171. doi: 10.1142/S0192415X02000168 PMID: 12067090
  162. Vayalil, P.K.; Kuttan, G.; Kuttan, R. Protective effects of Rasayanas on cyclophosphamide- and radiation-induced damage. J. Altern. Complement. Med., 2002, 8(6), 787-796. doi: 10.1089/10755530260511801 PMID: 12614532
  163. Menon, L.G.; Kuttan, R.; Kuttan, G. Effect of rasayanas in the inhibition of lung metastasis induced by B16F-10 melanoma cells. J. Exp. Clin. Cancer Res., 1997, 16(4), 365-368. PMID: 9505206
  164. Diasio, R.B.; Harris, B.E. Clinical pharmacology of 5-fluorouracil. Clin. Pharmacokinet., 1989, 16(4), 215-237. doi: 10.2165/00003088-198916040-00002 PMID: 2656050
  165. Anand, A.J. Fluorouracil Cardiotoxicity. Ann. Pharmacother., 1994, 28(3), 374-378. doi: 10.1177/106002809402800314 PMID: 8193429
  166. Longley, D.B.; Harkin, D.P.; Johnston, P.G. 5-Fluorouracil: Mechanisms of action and clinical strategies. Nat. Rev. Cancer, 2003, 3(5), 330-338. doi: 10.1038/nrc1074 PMID: 12724731
  167. Sun, X.X.; Dai, M.S.; Lu, H. 5-fluorouracil activation of p53 involves an MDM2-ribosomal protein interaction. J. Biol. Chem., 2007, 282(11), 8052-8059. doi: 10.1074/jbc.M610621200 PMID: 17242401
  168. Wigmore, P.M.; Mustafa, S.; El-Beltagy, M.; Lyons, L.; Umka, J.; Bennett, G. Effects of 5-FU. Adv Exp Med Biol., 2010, 678, 157-164. doi: 10.1007/978-1-4419-6306-2_20
  169. Steger, F.; Hautmann, M.G.; Kölbl, O. 5-FU-induced cardiac toxicity - an underestimated problem in radiooncology? Radiat. Oncol., 2012, 7(1), 212. doi: 10.1186/1748-717X-7-212 PMID: 23241239
  170. Zhang, D.; Ma, J. Mitochondrial dynamics in rat heart induced by 5-fluorouracil. Med. Sci. Monit., 2018, 24, 6666-6672. doi: 10.12659/MSM.910537 PMID: 30240386
  171. Shiga, T.; Hiraide, M. Cardiotoxicities of 5-fluorouracil and other fluoropyrimidines. Curr. Treat. Options Oncol., 2020, 21(4), 27. doi: 10.1007/s11864-020-0719-1 PMID: 32266582
  172. Dasgeb, B.; Kornreich, D.; McGuinn, K.; Okon, L.; Brownell, I.; Sackett, D.L. Colchicine: An ancient drug with novel applications. Br. J. Dermatol., 2018, 178(2), 350-356. doi: 10.1111/bjd.15896 PMID: 28832953
  173. Khanna, D.; Fitzgerald, J.D.; Khanna, P.P.; Bae, S.; Singh, M.K.; Neogi, T.; Pillinger, M.H.; Merill, J.; Lee, S.; Prakash, S.; Kaldas, M.; Gogia, M.; Perez-Ruiz, F.; Taylor, W.; Lioté, F.; Choi, H.; Singh, J.A.; Dalbeth, N.; Kaplan, S.; Niyyar, V.; Jones, D.; Yarows, S.A.; Roessler, B.; Kerr, G.; King, C.; Levy, G.; Furst, D.E.; Edwards, N.L.; Mandell, B.; Schumacher, H.R.; Robbins, M.; Wenger, N.; Terkeltaub, R. 2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res. (Hoboken), 2012, 64(10), 1431-1446. doi: 10.1002/acr.21772 PMID: 23024028
  174. Caviston, J.P.; Holzbaur, E.L.F. Microtubule motors at the intersection of trafficking and transport. Trends Cell Biol., 2006, 16(10), 530-537. doi: 10.1016/j.tcb.2006.08.002 PMID: 16938456
  175. Bakhta, O.; Blanchard, S.; Guihot, A.L.; Tamareille, S.; Mirebeau-Prunier, D.; Jeannin, P.; Prunier, F. Cardioprotective role of colchicine against inflammatory injury in a rat model of acute myocardial infarction. J. Cardiovasc. Pharmacol. Ther., 2018, 23(5), 446-455. doi: 10.1177/1074248418763611 PMID: 29658326
  176. Forrat, R.; Sebbag, L.; Ferrera, R.; Hadour, G.; Canet, E.; Tabib, A.; de Lorgeril, M. Effect of colchicine on circulating and myocardial neutrophils and on infarct size in a canine model of ischemia and reperfusion. J. Cardiovasc. Pharmacol., 1996, 27(6), 876-883. doi: 10.1097/00005344-199606000-00016 PMID: 8761856
  177. Couzin-Frankel, J. Anti-inflammatory prevents heart attacks; American Association for the Advancement of Science, 2017. doi: 10.1126/science.357.6354.855
  178. Safarpour, S; Safarpour, S; Pirzadeh, M; Moghadamnia, AA; Ebrahimpour, A; Shirafkan, F Colchicine ameliorates 5-fluorouracil-induced cardiotoxicity in rats. Oxid Med Cell Longev, 2022, 2022, 6194532.
  179. Miltenburg, N.C.; Boogerd, W. Chemotherapy-induced neuropathy: A comprehensive survey. Cancer Treat. Rev., 2014, 40(7), 872-882. doi: 10.1016/j.ctrv.2014.04.004 PMID: 24830939
  180. Jaggi, A.S.; Singh, N. Mechanisms in cancer-chemotherapeutic drugs-induced peripheral neuropathy. Toxicology, 2012, 291(1-3), 1-9. doi: 10.1016/j.tox.2011.10.019 PMID: 22079234
  181. Egan, M.; Burke, E.; Meskell, P.; MacNeela, P.; Dowling, M. Quality of life and resilience related to chemotherapy-induced peripheral neuropathy in patients post treatment with platinums and taxanes. J. Res. Nurs., 2015, 20(5), 385-398. doi: 10.1177/1744987115574296
  182. Wolf, S.; Barton, D.; Kottschade, L.; Grothey, A.; Loprinzi, C. Chemotherapy-induced peripheral neuropathy: Prevention and treatment strategies. Eur. J. Cancer, 2008, 44(11), 1507-1515. doi: 10.1016/j.ejca.2008.04.018 PMID: 18571399
  183. Beijers, A.J.M.; Vreugdenhil, G.; Oerlemans, S.; Eurelings, M.; Minnema, M.C.; Eeltink, C.M.; van de Poll-Franse, L.V.; Mols, F. Chemotherapy-induced neuropathy in multiple myeloma: Influence on quality of life and development of a questionnaire to compose common toxicity criteria grading for use in daily clinical practice. Support. Care Cancer, 2016, 24(6), 2411-2420. doi: 10.1007/s00520-015-3032-y PMID: 26634561
  184. Smith, J.A.; Benbow, S.J. , 2015.
  185. Hausheer, F.H.; Schilsky, R.L.; Bain, S.; Berghorn, E.J.; Lieberman, F. Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy.Seminars in oncology; Elsevier, 2006, pp. 15-49. doi: 10.1053/j.seminoncol.2005.12.010
  186. Grothey, A. Clinical management of oxaliplatin-associated neurotoxicity. Clin. Colorectal Cancer, 2005, 5(Suppl. 1), S38-S46. doi: 10.3816/CCC.2005.s.006 PMID: 15871765
  187. Kushlaf, H.A. Emerging toxic neuropathies and myopathies. Neurol. Clin., 2011, 29(3), 679-687. doi: 10.1016/j.ncl.2011.05.009 PMID: 21803218
  188. Kuncl, R.W.; George, E.B. Toxic neuropathies and myopathies. Curr. Opin. Neurol., 1993, 6(5), 695-704. doi: 10.1097/00019052-199310000-00004 PMID: 8293140
  189. Flatters, S.J.L.; Xiao, W.H.; Bennett, G.J. Acetyl-l-carnitine prevents and reduces paclitaxel-induced painful peripheral neuropathy. Neurosci. Lett., 2006, 397(3), 219-223. doi: 10.1016/j.neulet.2005.12.013 PMID: 16406309
  190. Cavaletti, G. Calcium and magnesium prophylaxis for oxaliplatin-related neurotoxicity: Is it a trade-off between drug efficacy and toxicity? Oncologist, 2011, 16(12), 1667-1668. doi: 10.1634/theoncologist.2011-0343 PMID: 22128117
  191. Ta, L.E.; Schmelzer, J.D.; Bieber, A.J.; Loprinzi, C.L.; Sieck, G.C.; Brederson, J.D.; Low, P.A.; Windebank, A.J. A novel and selective poly (ADP-ribose) polymerase inhibitor ameliorates chemotherapy-induced painful neuropathy. PLoS One, 2013, 8(1), e54161. doi: 10.1371/journal.pone.0054161 PMID: 23326593
  192. Wolf, R.C.; Sambataro, F.; Vasic, N.; Schönfeldt-Lecuona, C.; Ecker, D.; Landwehrmeyer, B. Aberrant connectivity of lateral prefrontal networks in presymptomatic Huntington’s disease. Exp. Neurol., 2008, 213(1), 137-144. doi: 10.1016/j.expneurol.2008.05.017 PMID: 18588876
  193. Ceresa, C.; Cavaletti, G. Drug transporters in chemotherapy induced peripheral neurotoxicity: Current knowledge and clinical implications. Curr. Med. Chem., 2011, 18(3), 329-341. doi: 10.2174/092986711794839160 PMID: 21143122
  194. Jordan, M. Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Curr. Med. Chem. Anticancer Agents, 2012, 2(1), 1-17. doi: 10.2174/1568011023354290 PMID: 12678749
  195. Verstappen, C.C.P.; Koeppen, S.; Heimans, J.J.; Huijgens, P.C.; Scheulen, M.E.; Strumberg, D.; Kiburg, B.; Postma, T.J. Dose-related vincristine-induced peripheral neuropathy with unexpected off-therapy worsening. Neurology, 2005, 64(6), 1076-1077. doi: 10.1212/01.WNL.0000154642.45474.28 PMID: 15781834
  196. Sharma, V.; Singh, I.; Chaudhary, P. Acorus calamus (The Healing Plant): A review on its medicinal potential, micropropagation and conservation. Nat. Prod. Res., 2014, 28(18), 1454-1466. doi: 10.1080/14786419.2014.915827 PMID: 24824923
  197. Shah, P.; Deshmukh, P.B.; Joshi, S.V.; Ghag, M.; Kulkarni, Y.; Vyas, B.; Shah, D.R. Toxicity study of ethanolic extract of Acorus calamus rhizome. Int. J. Green Pharm., 2012, 6(1), 29. doi: 10.4103/0973-8258.97119
  198. Akram, M.; Akhtar, N.; Asif, H.M.; Shah, P.A.; Saeed, T.; Mahmood, A. Butea monosperma Lam.: A review. J. Med. Plants Res., 2011, 5, 3994-3996.
  199. Madhavi, A. An overview of Butea monosperma (Flame of Forest). World J. Pharm. Pharm. Sci., 2013, 3, 307-319.
  200. Rahn, E.J.; Makriyannis, A.; Hohmann, A.G. Activation of cannabinoid CB 1 and CB 2 receptors suppresses neuropathic nociception evoked by the chemotherapeutic agent vincristine in rats. Br. J. Pharmacol., 2007, 152(5), 765-777. doi: 10.1038/sj.bjp.0707333 PMID: 17572696
  201. Nagarkatti, P.; Pandey, R.; Rieder, S.A.; Hegde, V.L.; Nagarkatti, M. Cannabinoids as novel anti-inflammatory drugs. Future Med. Chem., 2009, 1(7), 1333-1349. doi: 10.4155/fmc.09.93 PMID: 20191092
  202. Rahn, E.J.; Hohmann, A.G. Cannabinoids as pharmacotherapies for neuropathic pain: From the bench to the bedside. Neurotherapeutics, 2009, 6(4), 713-737. doi: 10.1016/j.nurt.2009.08.002 PMID: 19789075
  203. Isah, T. Rethinking Ginkgo biloba L.: Medicinal uses and conservation. Pharmacogn. Rev., 2015, 9(18), 140-148. doi: 10.4103/0973-7847.162137 PMID: 26392712
  204. Pattanayak, P.; Behera, P.; Das, D.; Panda, S. Ocimum sanctum Linn. A reservoir plant for therapeutic applications: An overview. Pharmacogn. Rev., 2010, 4(7), 95-105. doi: 10.4103/0973-7847.65323 PMID: 22228948
  205. Kelm, M.A.; Nair, M.G.; Strasburg, G.M.; DeWitt, D.L. Antioxidant and cyclooxygenase inhibitory phenolic compounds from Ocimum sanctum Linn. Phytomedicine, 2000, 7(1), 7-13. doi: 10.1016/S0944-7113(00)80015-X PMID: 10782484
  206. Ramappa, V.; Aithal, G.P. Hepatotoxicity related to anti-tuberculosis drugs: Mechanisms and management. J. Clin. Exp. Hepatol., 2013, 3(1), 37-49. doi: 10.1016/j.jceh.2012.12.001 PMID: 25755470
  207. Oun, R.; Moussa, Y.E.; Wheate, N.J. The side effects of platinum-based chemotherapy drugs: A review for chemists. Dalton Trans., 2018, 47(19), 6645-6653. doi: 10.1039/C8DT00838H PMID: 29632935
  208. Quintanilha, J.C.F.; de Sousa, V.M.; Visacri, M.B.; Amaral, L.S.; Santos, R.M.M.; Zambrano, T.; Salazar, L.A.; Moriel, P. Involvement of cytochrome P450 in cisplatin treatment: Implications for toxicity. Cancer Chemother. Pharmacol., 2017, 80(2), 223-233. doi: 10.1007/s00280-017-3358-x PMID: 28612092
  209. Lu, Y.; Cederbaum, A.I. Cisplatin-induced hepatotoxicity is enhanced by elevated expression of cytochrome P450 2E1. Toxicol. Sci., 2006, 89(2), 515-523. doi: 10.1093/toxsci/kfj031 PMID: 16251482
  210. Kamble, P.R.; Bhiwgade, D.A. Cisplatin induced histological and ultrastructural alterations in liver tissue of rat. J. Cytol. Histol., 2011, 2(6), 128. doi: 10.4172/2157-7099.1000128
  211. Lu, Y.; Cederbaum, A.I. Cytochrome P450s and alcoholic liver disease. Curr. Pharm. Des., 2018, 24(14), 1502-1517. doi: 10.2174/1381612824666180410091511 PMID: 29637855
  212. Pratibha, R.; Sameer, R.; Rataboli, P.V.; Bhiwgade, D.A.; Dhume, C.Y. Enzymatic studies of cisplatin induced oxidative stress in hepatic tissue of rats. Eur. J. Pharmacol., 2006, 532(3), 290-293. doi: 10.1016/j.ejphar.2006.01.007 PMID: 16458885
  213. Singh, N.; Magotra, R.; Sharma, A.K.; Ahmed, M.; Khajuria, V. Effect of cisplatin on liver of male albino rats. J. Evol. Med. Dent. Sci., 2015, 4(52), 8993-8998. doi: 10.14260/jemds/2015/1305
  214. Abd Rashid, N.; Abd Halim, S.A.S.; Teoh, S.L.; Budin, S.B.; Hussan, F.; Adib Ridzuan, N.R.; Abdul Jalil, N.A. The role of natural antioxidants in cisplatin-induced hepatotoxicity. Biomed. Pharmacother., 2021, 144, 112328. doi: 10.1016/j.biopha.2021.112328 PMID: 34653753
  215. Aeri, V.; Ilyas, U.; Katare, D.P.; Naseef, P. A review on hepatoprotective and immunomodulatory herbal plants. Pharmacogn. Rev., 2016, 10(19), 66-70. doi: 10.4103/0973-7847.176544 PMID: 27041876
  216. Kim, Y.S.; Hwang, J.W.; Sung, S.H.; Jeon, Y.J.; Jeong, J.H.; Jeon, B.T.; Moon, S.H.; Park, P.J. Antioxidant activity and protective effect of extract of Celosia cristata L. flower on tert-butyl hydroperoxide-induced oxidative hepatotoxicity. Food Chem., 2015, 168, 572-579. doi: 10.1016/j.foodchem.2014.07.106 PMID: 25172750
  217. Sharifi-Rigi, A.; Heidarian, E.; Amini, S.A. Protective and anti-inflammatory effects of hydroalcoholic leaf extract of Origanum vulgare on oxidative stress, TNF-α gene expression and liver histological changes in paraquat-induced hepatotoxicity in rats. Arch. Physiol. Biochem., 2019, 125(1), 56-63. doi: 10.1080/13813455.2018.1437186 PMID: 29425067
  218. Zhao, L.; Zhang, N.; Yang, D.; Yang, M.; Guo, X.; He, J.; Wu, W.; Ji, B.; Cheng, Q.; Zhou, F. Protective effects of five structurally diverse flavonoid subgroups against chronic alcohol-induced hepatic damage in a mouse model. Nutrients, 2018, 10(11), 1754. doi: 10.3390/nu10111754 PMID: 30441755
  219. Hosseinzadeh, A.; Bahrampour Juybari, K.; Fatemi, M.J.; Kamarul, T.; Tekiyehmaroof, N. Protective effect of ginger (Zingiber officinale roscoe) extract against oxidative stress and mitochondrial apoptosis induced by interleukin-1β in cultured chondrocytes. Cells Tissues Organs, 2017, 204(5-6), 241-50.
  220. Michael, O.E.; Titilayo, O.B.; Mohammed, A.U. Protective effect of ethanolic extract of Cucurbita maxima (PUMPKIN) leaf on acetaminophen-induced acute liver toxicity. J. Pharmacogn. Phytother., 2018, 10(8), 142-148. doi: 10.5897/JPP2018.0498
  221. Metri, K.; Bhargav, H.; Chowdhury, P.; Koka, P.S. Ayurveda for chemo-radiotherapy induced side effects in cancer patients. J. Stem Cells, 2013, 8(2), 115-129. PMID: 24698988
  222. Frassová, Z.; Rudá-Kučerová, J. Milk Thistle (Silybum Marianum) as a supportive phytotherapeutic agent in oncology. Klin. Onkol., 2017, 30(6), 426-432. doi: 10.14735/amko2017426 PMID: 29271213
  223. Ito, T.; Urushima, H.; Sakaue, M.; Yukawa, S.; Honda, H.; Hirai, K.; Igura, T.; Hayashi, N.; Maeda, K.; Kitagawa, T.; Kondo, K. Reduction of adverse effects by a mushroom product, active hexose correlated compound (AHCC) in patients with advanced cancer during chemotherapy-the significance of the levels of HHV-6 DNA in saliva as a surrogate biomarker during chemotherapy. Nutr. Cancer, 2014, 66(3), 377-382. doi: 10.1080/01635581.2014.884232 PMID: 24611562
  224. Man, Q.; Deng, Y.; Li, P.; Ma, J.; Yang, Z.; Yang, X.; Zhou, Y.; Yan, X. Licorice ameliorates cisplatin-induced hepatotoxicity through antiapoptosis, antioxidative stress, anti-inflammation, and acceleration of metabolism. Front. Pharmacol., 2020, 11, 563750. doi: 10.3389/fphar.2020.563750 PMID: 33240085
  225. Awika, J.M.; Rooney, L.W. Sorghum phytochemicals and their potential impact on human health. Phytochemistry, 2004, 65(9), 1199-1221. doi: 10.1016/j.phytochem.2004.04.001 PMID: 15184005
  226. Rohdewald, P. A review of the French maritime pine bark extract (Pycnogenol®), a herbal medication with a diverse clinical pharmacology. Int. J. Clin. Pharmacol. Ther., 2002, 40(4), 158-168. doi: 10.5414/CPP40158 PMID: 11996210
  227. González-Juárez, D.E.; Escobedo-Moratilla, A.; Flores, J.; Hidalgo-Figueroa, S.; Martínez-Tagüeña, N.; Morales-Jiménez, J.; Muñiz-Ramírez, A.; Pastor-Palacios, G.; Pérez-Miranda, S.; Ramírez-Hernández, A.; Trujillo, J.; Bautista, E. A review of the Ephedra genus: Distribution, ecology, ethnobotany, phytochemistry and pharmacological properties. Molecules, 2020, 25(14), 3283. doi: 10.3390/molecules25143283 PMID: 32698308
  228. Hyuga, S.; Hyuga, M.; Oshima, N.; Maruyama, T.; Kamakura, H.; Yamashita, T.; Yoshimura, M.; Amakura, Y.; Hakamatsuka, T.; Odaguchi, H.; Goda, Y.; Hanawa, T. Ephedrine alkaloids-free Ephedra Herb extract: A safer alternative to ephedra with comparable analgesic, anticancer, and anti-influenza activities. J. Nat. Med., 2016, 70(3), 571-583. doi: 10.1007/s11418-016-0979-z PMID: 26943796
  229. Priyadarsini, K.I.; Maity, D.K.; Naik, G.H.; Kumar, M.S.; Unnikrishnan, M.K.; Satav, J.G.; Mohan, H. Role of phenolic O-H and methylene hydrogen on the free radical reactions and antioxidant activity of curcumin. Free Radic. Biol. Med., 2003, 35(5), 475-484. doi: 10.1016/S0891-5849(03)00325-3 PMID: 12927597
  230. Hatcher, H.; Planalp, R.; Cho, J.; Torti, F.M.; Torti, S.V. Curcumin: From ancient medicine to current clinical trials. Cell. Mol. Life Sci., 2008, 65(11), 1631-1652. doi: 10.1007/s00018-008-7452-4 PMID: 18324353
  231. Miller, R.P.; Tadagavadi, R.K.; Ramesh, G.; Reeves, W.B. Mechanisms of Cisplatin nephrotoxicity. Toxins (Basel), 2010, 2(11), 2490-2518. doi: 10.3390/toxins2112490 PMID: 22069563
  232. Perazella, M.A.; Moeckel, G.W. Nephrotoxicity from chemotherapeutic agents: Clinical manifestations, pathobiology, and prevention/therapy. Seminars in nephrology; Elsevier, 2010, pp. 570-581. doi: 10.1016/j.semnephrol.2010.09.005
  233. Lameire, N. Nephrotoxicity of recent anti-cancer agents. Clin. Kidney J., 2014, 7(1), 11-22. doi: 10.1093/ckj/sft135 PMID: 25859345
  234. Sadeghi, F.; Nematbakhsh, M.; Noori-Diziche, A.; Eshraghi-Jazi, F.; Talebi, A.; Nasri, H.; Mansouri, A.; Dehghani, A.; Saberi, S.; Shirdavani, S.; Ashrafi, F. Protective effect of pomegranate flower extract against gentamicin-induced renal toxicity in male rats. J. Renal Inj. Prev., 2015, 4(2), 45-50. PMID: 26060837
  235. Pourjabali, M.; Mohammadrezaei-Khorramabadi, R.; Abbaszadeh, S.; Naghdi, N.; Naji-Haddadi, S.; Bahmani, F. Medicinal plants used for hypertension. J Pharm Sci Res., 2017, 9(5), 537.
  236. Jivad, N.; Bahmani, M.; Asadi-Samani, M. A review of the most important medicinal plants effective on wound healing on ethnobotany evidence of Iran. Pharm. Lett., 2016, 8(2), 353-357.
  237. Kooti, W.; Hasanzadeh-Noohi, Z.; Sharafi-Ahvazi, N.; Asadi-Samani, M.; Ashtary-Larky, D. Phytochemistry, pharmacology, and therapeutic uses of black seed (Nigella sativa). Chin. J. Nat. Med., 2016, 14(10), 732-745. doi: 10.1016/S1875-5364(16)30088-7 PMID: 28236403
  238. Sani, M.R.M.; Asadi-Samani, M.; Rouhi-Boroujeni, H.; Banitalebi-Dehkordi, M. Phytopharmacology and phytotherapy of regulatory T cells: A new approach to treat multiple sclerosis. Pharm. Lett., 2016, 8(3), 215-220.
  239. Rouhi-Boroujeni, H.; Asadi-Samani, M.; Moradi, M.T. A review of the medicinal plants effective on headache based on the ethnobotanical documents of Iran. Pharm. Lett., 2016, 8(3), 37-42.
  240. Parsaei, P.; Bahmani, M.; Karimi, M.; Naghdi, N.; Asadi-Samani, M.; Rafieian-Kopaei, M. A review of analgesic medicinal plants in Iran. Pharm. Lett., 2016, 8(2), 43-51.
  241. Parsaei, P.; Bahmani, M.; Naghdi, N.; Asadi-Samani, M.; Rafieian-Kopaei, M. The most important medicinal plants effective on constipation by the ethnobotanical documents in Iran: A review. Pharm. Lett., 2016, 8(2), 188-194.
  242. Çayır, K.; Karadeniz, A.; Şimşek, N.; Yıldırım, S.; Karakuş, E.; Kara, A.; Akkoyun, H.T.; Şengül, E. Pomegranate seed extract attenuates chemotherapy-induced acute nephrotoxicity and hepatotoxicity in rats. J. Med. Food, 2011, 14(10), 1254-1262. doi: 10.1089/jmf.2010.0286 PMID: 21548807
  243. Boroushaki, M.T.; Rajabian, A.; Farzadnia, M.; Hoseini, A.; Poorlashkari, M.; Taghavi, A.; Dolati, K.; Bazmandegan, G. Protective effect of pomegranate seed oil against cisplatin-induced nephrotoxicity in rat. Ren. Fail., 2015, 37(8), 1338-1343. doi: 10.3109/0886022X.2015.1073496 PMID: 26288026
  244. Karwasra, R.; Kalra, P.; Gupta, Y.K.; Saini, D.; Kumar, A.; Singh, S. Antioxidant and anti-inflammatory potential of pomegranate rind extract to ameliorate cisplatin-induced acute kidney injury. Food Funct., 2016, 7(7), 3091-3101. doi: 10.1039/C6FO00188B PMID: 27273121
  245. Khan, S.A.; Priyamvada, S.; Khan, W.; Khan, S.; Farooq, N.; Yusufi, A.N.K. Studies on the protective effect of green tea against cisplatin induced nephrotoxicity. Pharmacol. Res., 2009, 60(5), 382-391. doi: 10.1016/j.phrs.2009.07.007 PMID: 19647078
  246. Ko, J-L.; Tsai, C-H.; Liu, T-C.; Lin, M-Y.; Lin, H-L.; Ou, C-C. Differential effects of grape juice on gastric emptying and renal function from cisplatin-induced acute adverse toxicity. Hum. Exp. Toxicol., 2016, 35(8), 808-817. doi: 10.1177/0960327115607079 PMID: 26429932
  247. Mazumder, P.B.; Devi, H.P. Methanolic Extract of Curcuma caesia Roxb. prevents the toxicity caused by Cyclophosphamide to bone marrow cells, liver and kidney of mice. Pharmacognosy Res., 2016, 8(1), 43-49. doi: 10.4103/0974-8490.171106 PMID: 26941535
  248. Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2018. CA Cancer J. Clin., 2018, 68(1), 7-30. doi: 10.3322/caac.21442 PMID: 29313949
  249. Pfeiffer, P.; Köhne, C.H.; Qvortrup, C. The changing face of treatment for metastatic colorectal cancer. Expert Rev. Anticancer Ther., 2019, 19(1), 61-70. doi: 10.1080/14737140.2019.1543593 PMID: 30381969
  250. Schmoll, H.J.; Van Cutsem, E.; Stein, A.; Valentini, V.; Glimelius, B.; Haustermans, K.; Nordlinger, B.; van de Velde, C.J.; Balmana, J.; Regula, J.; Nagtegaal, I.D.; Beets-Tan, R.G.; Arnold, D.; Ciardiello, F.; Hoff, P.; Kerr, D.; Köhne, C.H.; Labianca, R.; Price, T.; Scheithauer, W.; Sobrero, A.; Tabernero, J.; Aderka, D.; Barroso, S.; Bodoky, G.; Douillard, J.Y.; El Ghazaly, H.; Gallardo, J.; Garin, A.; Glynne-Jones, R.; Jordan, K.; Meshcheryakov, A.; Papamichail, D.; Pfeiffer, P.; Souglakos, I.; Turhal, S.; Cervantes, A. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann. Oncol., 2012, 23(10), 2479-2516. doi: 10.1093/annonc/mds236 PMID: 23012255
  251. Lalla, R.V.; Bowen, J.; Barasch, A.; Elting, L.; Epstein, J.; Keefe, D.M.; McGuire, D.B.; Migliorati, C.; Nicolatou-Galitis, O.; Peterson, D.E.; Raber-Durlacher, J.E.; Sonis, S.T.; Elad, S. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer, 2014, 120(10), 1453-1461. doi: 10.1002/cncr.28592 PMID: 24615748
  252. Boussios, S.; Pentheroudakis, G.; Katsanos, K.; Pavlidis, N. Systemic treatment-induced gastrointestinal toxicity: Incidence, clinical presentation and management. Ann. Gastroenterol., 2012, 25(2), 106-118. PMID: 24713845
  253. Andreyev, H.J.N.; Lalji, A.; Mohammed, K.; Muls, A.C.G.; Watkins, D.; Rao, S.; Starling, N.; Chau, I.; Cruse, S.; Pitkaaho, V.; Matthews, J.; Caley, L.; Pittordou, V.; Adams, C.; Wedlake, L. The FOCCUS study: A prospective evaluation of the frequency, severity and treatable causes of gastrointestinal symptoms during and after chemotherapy. Support. Care Cancer, 2021, 29(3), 1443-1453. doi: 10.1007/s00520-020-05610-x PMID: 32676853
  254. Liu, W.; Ge, T.; Pan, Z.; Leng, Y.; Lv, J.; Li, B. The effects of herbal medicine on epilepsy. Oncotarget, 2017, 8(29), 48385-48397. doi: 10.18632/oncotarget.16801 PMID: 28423368
  255. Zhong, L.L.D.; Chen, H.Y.; Cho, W.C.S.; Meng, X.; Tong, Y. The efficacy of Chinese herbal medicine as an adjunctive therapy for colorectal cancer: A systematic review and meta-analysis. Complement. Ther. Med., 2012, 20(4), 240-252. doi: 10.1016/j.ctim.2012.02.004 PMID: 22579437
  256. McCulloch, M.; Ly, H.; Broffman, M.; See, C.; Clemons, J.; Chang, R. Chinese herbal medicine and fluorouracil-based chemotherapy for colorectal cancer: A quality-adjusted meta-analysis of randomized controlled trials. Integr. Cancer Ther., 2016, 15(3), 285-307. doi: 10.1177/1534735416638738 PMID: 27151587
  257. Lin, S.; An, X.; Guo, Y.; Gu, J.; Xie, T.; Wu, Q.; Sui, X. Meta-analysis of astragalus-containing traditional Chinese medicine combined with chemotherapy for colorectal cancer: Efficacy and safety to tumor response. Front. Oncol., 2019, 9, 749. doi: 10.3389/fonc.2019.00749 PMID: 31456940
  258. Liu, S.; Zhang, K.; Hu, X. Comparative efficacy and safety of Chinese medicine injections combined with capecitabine and oxaliplatin chemotherapies in treatment of colorectal cancer: A bayesian network meta-analysis. Front. Pharmacol., 2022, 13, 1004259. doi: 10.3389/fphar.2022.1004259 PMID: 36523501
  259. Motoo, Y.; Seki, T.; Tsutani, K. Traditional Japanese medicine, Kampo: Its history and current status. Chin. J. Integr. Med., 2011, 17(2), 85-87. doi: 10.1007/s11655-011-0653-y PMID: 21390572
  260. Hesketh, P.J. Chemotherapy-induced nausea and vomiting. N. Engl. J. Med., 2008, 358(23), 2482-2494. doi: 10.1056/NEJMra0706547 PMID: 18525044
  261. Roila, F.; Herrstedt, J.; Aapro, M.; Gralla, R.J.; Einhorn, L.H.; Ballatori, E.; Bria, E.; Clark-Snow, R.A.; Espersen, B.T.; Feyer, P.; Grunberg, S.M.; Hesketh, P.J.; Jordan, K.; Kris, M.G.; Maranzano, E.; Molassiotis, A.; Morrow, G.; Olver, I.; Rapoport, B.L.; Rittenberg, C.; Saito, M.; Tonato, M.; Warr, D. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: Results of the Perugia consensus conference. Ann. Oncol., 2010, 21(Suppl. 5), v232-v243. doi: 10.1093/annonc/mdq194 PMID: 20555089
  262. De Vry, J.; Schreiber, R. Effects of selected serotonin 5-HT 1 and 5-HT 2 receptor agonists on feeding behavior: Possible mechanisms of action. Neurosci. Biobehav. Rev., 2000, 24(3), 341-353. doi: 10.1016/S0149-7634(99)00083-4 PMID: 10781694
  263. Tatsuta, M.; Iishi, H. Effect of treatment with Liu-Jun-Zi-Tang (TJ-43) on gastric emptying and gastrointestinal symptoms in dyspeptic patients. Aliment. Pharmacol. Ther., 1993, 7(4), 459-462. doi: 10.1111/j.1365-2036.1993.tb00120.x PMID: 8218760
  264. Ohkawa, H.; Ohishi, N.; Yagi, K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal. Biochem., 1979, 95(2), 351-358. doi: 10.1016/0003-2697(79)90738-3 PMID: 36810
  265. Takeda, H.; Sadakane, C.; Hattori, T.; Katsurada, T.; Ohkawara, T.; Nagai, K.; Asaka, M. Rikkunshito, an herbal medicine, suppresses cisplatin-induced anorexia in rats via 5-HT2 receptor antagonism. Gastroenterology, 2008, 134(7), 2004-2013. doi: 10.1053/j.gastro.2008.02.078 PMID: 18439428
  266. Yakabi, K.; Kurosawa, S.; Tamai, M.; Yuzurihara, M.; Nahata, M.; Ohno, S.; Ro, S.; Kato, S.; Aoyama, T.; Sakurada, T.; Takabayashi, H.; Hattori, T. Rikkunshito and 5-HT2C receptor antagonist improve cisplatin-induced anorexia via hypothalamic ghrelin interaction. Regul. Pept., 2010, 161(1-3), 97-105. doi: 10.1016/j.regpep.2010.02.003 PMID: 20171995
  267. Kase, Y.; Hayakawa, T.; Aburada, M.; Komatsu, Y.; Kamataki, T. Preventive effects of Hange-shashin-to on irinotecan hydrochloride-caused diarrhea and its relevance to the colonic prostaglandin E2 and water absorption in the rat. Jpn. J. Pharmacol., 1997, 75(4), 407-413. doi: 10.1254/jjp.75.407 PMID: 9469647
  268. Narita, M.; Nagai, E.; Hagiwara, H.; Aburada, M.; Yokoi, T.; Kamataki, T. Inhibition of β-glucuronidase by natural glucuronides of Kampo, medicines using glucuronide of SN-38 (7-ethyl-10-hydroxycamptothecin) as a substrate. Xenobiotica, 1993, 23(1), 5-10. doi: 10.3109/00498259309059356 PMID: 8484262
  269. Takasuna, K.; Kasai, Y.; Kitano, Y.; Mori, K.; Kobayashi, R.; Hagiwara, T.; Kakihata, K.; Hirohashi, M.; Nomura, M.; Nagai, E.; Kamataki, T. Protective effects of kampo medicines and baicalin against intestinal toxicity of a new anticancer camptothecin derivative, irinotecan hydrochloride (CPT-11), in rats. Jpn. J. Cancer Res., 1995, 86(10), 978-984. doi: 10.1111/j.1349-7006.1995.tb03010.x PMID: 7493918
  270. Perazella, M.A. Drug use and nephrotoxicity in the intensive care unit. Kidney Int., 2012, 81(12), 1172-1178. doi: 10.1038/ki.2010.475 PMID: 21124300

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bentham Science Publishers, 2024